Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Haemonetics posts Q2 FY27 results online and schedules investor call for November 5, 2026.

What the company is saying

Haemonetics Corporation (NYSE:HAE) is informing investors that its financial results for the second quarter of fiscal year 2027, which ended September 26, 2026, are now available on its Investor Relations website. The company is emphasizing transparency and accessibility by providing both the earnings release and a supplemental presentation online. It is also inviting investors and analysts to a conference call and webcast at 8:00 a.m. ET on November 5, 2026, with registration required for dial-in details and a personalized PIN. The company highlights that a replay of the call will be accessible starting at 11:00 a.m. ET the same day and will remain available for one year. Haemonetics briefly describes its business segments, mentioning proprietary technologies in Apheresis and MedSurg, but does not provide operational or financial performance details in this announcement. The tone is neutral and procedural, focusing on logistics and access rather than performance or outlook.

What the data suggests

The announcement provides only logistical details: the reporting period ended September 26, 2026, and the financial results are available online. The conference call is scheduled for November 5, 2026, with a replay available for one year. No financial figures, operational metrics, or year-over-year comparisons are disclosed in the text, so the company's financial trajectory cannot be assessed from this release. The only hard facts are the timing of the results release, the availability of supporting materials, and the schedule for investor communications. The brief descriptions of the Apheresis and MedSurg businesses are generic and not supported by quantitative evidence. Investors must consult the posted earnings release and presentation for substantive financial and operational data.

Analysis

The announcement is a procedural notice regarding the availability of Haemonetics Corporation's second quarter fiscal 2027 financial results and related investor communications. It does not disclose any financial or operational metrics, nor does it make forward-looking projections about company performance or future benefits. The only forward-looking elements are logistical (the timing of the conference call and webcast replay), which are imminent and routine. There is no promotional or exaggerated language about the company's business or prospects; the brief descriptions of business segments are generic and not paired with any claims of recent or future performance. No capital outlay or investment program is mentioned. The gap between narrative and evidence is nonexistent, as the narrative is strictly factual and administrative.

Risk flags

• ●The announcement does not include any financial or operational metrics, requiring investors to seek out the full results elsewhere. This limits immediate transparency and delays direct assessment of company performance.
• ●The brief business descriptions are not substantiated with data, which may obscure any recent changes in segment performance or strategic direction until investors review the detailed materials.
• ●Reliance on external documents for substantive information introduces the risk that key financial or operational issues are not highlighted in the summary announcement, potentially delaying market reaction.

Bottom line

This is a routine procedural update: Haemonetics has published its Q2 FY27 results online and set a same-day investor call. No financial or operational figures are disclosed in the announcement itself, so investors must access the posted materials for actionable insights. The company's messaging is neutral and focused on logistics, offering no new information about business performance or strategy. Immediate investment decisions cannot be made based on this notice alone; the real story will be in the detailed earnings release and supplemental presentation. The most important takeaway is that all substantive analysis depends on reviewing the full posted results.

Announcement summary

(NYSE:HAE) Haemonetics Corporation announced that its financial results for the second quarter of fiscal year 2027, which ended on September 26, 2026, are now available on the company's Investor Relations website at www.haemonetics.com. The company will host a conference call and webcast with investors and analysts to discuss and answer questions about these results at 8:00 a.m. ET on November 5, 2026. Participants can register for the call to receive dial-in details and a personalized PIN, and are recommended to join 10 minutes prior to the event start time. A live webcast will be accessible through the Investor Relations section of the Haemonetics website. A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 5, 2026, and will remain accessible for one year via the webcast link. Haemonetics has also posted its Second Quarter Fiscal 2027 Earnings Release and Second Quarter Fiscal 2027 Supplemental Earnings Presentation on its Investor Relations website, which will be referenced during the conference call and webcast. The company’s Apheresis business features proprietary technologies for plasma and blood collectors. The MedSurg business offers Blood Management Technologies and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies. Olga Guyette is Vice President-Investor Relations & Treasury, and David Trenk is Sr. Manager-Investor Relations.

Disagree with this article?